Technology for Analysis of miRNA Signatures (TAmiRS): a Novel Tool for Personalized Cancer Medicine

在每种类型的癌症中，有多种亚型表现出不同程度的攻击性行为， 不同的管理策略。因此，传统的“一刀切”癌症管理方法效率不高。 为了有效，癌症治疗应该通过使用患者特异性特征来个性化-这是癌症治疗的范例。 个性化癌症治疗miRNA是非常有前途的分子标记物，用于准确诊断癌症亚型， 每一种癌症亚型都可能与独特的定量miRNA特征相关。尽管尽了一切努力 癌症亚型的miRNA签名，甚至没有一个单一的miRNA签名被验证和批准用于临床使用。 miRNA特征的发现和验证需要（i）定量，（ii）高灵敏度， (iii)坚固耐用，（iv）能够同时分析多种miRNA，（v）成本有效，以及（vi）快速。这样的 技术并不存在，这可以说是我们在癌症中实际使用miRNA标签的主要挑战 药我们建议开发一种满足6个条件的miRNA特征分析技术（TAmiRS）， 这是一个新的发现，可以发现和验证miRNA签名。我们最近发明了一种乐器， 方法学方法，可以促进TAmiRS与其独特的能力，测量绝对量的多个 没有校准曲线的miRNA。不同实验室获得的TAmiRS结果可以汇总在一起， 分析，这是发现和验证miRNA签名的关键，需要分析数千名患者 样品当miRNA标签已经被验证时，TAmiRS可以用于临床中的癌症亚型诊断。 setup.了解癌症亚型将使医生能够选择最合适的治疗方法。这将是重要的一步 走向个性化癌症治疗

Within each type of cancer there are multiple subtypes that exhibit different levels of aggressive behaviour and require different management strategies. As a result, the classical "one-size-fits-all" approach in cancer management is not efficient. To be efficient, a cancer therapy should be personalized by using patient-specific characteristics - this is the paradigm of personalized cancer medicine. MiRNAs are very promising molecular markers for accurately diagnosing cancer subtypes as every cancer subtype is presumably associated with a unique quantitative miRNA signature. Despite all efforts to identify miRNA signatures of cancer subtypes, there is not even a single miRNA signature validated and approved for clinical use. Discovery and validation of miRNA signatures require a miRNA analysis technology that is (i) quantitative, (ii) highlysensitive, (iii) rugged, (iv) capable of simultaneously analyzing multiple miRNAs, (v) cost-effective, and (vi) rapid. Such a technology does not exist and this is arguably the major challenge on our way to practical use of miRNA signatures in cancer medicine. We propose to develop a Technology for Analysis of miRNA Signatures (TAmiRS), which satisfies the 6 requirements and can enable the discovery and validation of miRNA signatures. We recently invented instrumental and methodological approaches that can facilitate TAmiRS with its unique capability of measuring absolute amounts of multiple miRNAs without calibration curves. The TAmiRS results obtained in different laboratories can be pooled together for analysis, which is pivotal for discovery and validation of miRNA signatures requiring the analysis of thousands of patient samples. When a miRNA signature has been validated, TAmiRS can be used for cancer subtype diagnosis in a clinical setup. Knowing cancer subtypes will allow physicians to choose most suitable therapies. This will be a significant step towards personalized cancer medicine.